Downregulation of connective tissue growth factor reduces migration and invasiveness of osteosarcoma cells

Huang,Yinjun; Zhao,Shichang; Zhang,Changqing; Li,Xiaolin

doi:10.3892/mmr.2015.4701

Downregulation of connective tissue growth factor reduces migration and invasiveness of osteosarcoma cells

Authors:
- Yinjun Huang
- Shichang Zhao
- Changqing Zhang
- Xiaolin Li
View Affiliations

Affiliations: Department of Orthopedic Surgery, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, P.R. China
Published online on: December 22, 2015 https://doi.org/10.3892/mmr.2015.4701
Pages: 1888-1894

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As one of the most serious types of primary bone tumor, osteosarcoma (OSA) features metastatic lesions, and resistance to chemotherapy is common. The underlying mechanisms of these characteristics may account for the failure of treatments and the poor prognosis of patients with OSA. It has been reported that inhibition of Cyr61 suppresses OSA cell proliferation as it represents a target of statins. In addition to cystein‑rich protein 61 (Cyr61) and nephroblastoma overexpression, connective tissue growth factor (CTGF) is a member of the CCN family and may therefore exhibit effects on human OSA cells similar to those of Cyr61. In the current study, acridine orange/ethidium bromide staining were used to determine the rate of apoptosis. The present study demonstrated that small interfering RNA‑mediated silencing of CTGF promoted cell death and suppressed OSA cell migration and invasion, as indicated by wound healing and Transwell assays, while lentivirus‑mediated overexpression of CTGF reversed these effects. Furthermore, a colorimetric caspase assay demonstrated that CTGF knockdown enhanced the efficacy of chemotherapeutic drugs. The results of the present study provided a novel molecular target which may be utilized for the treatment of metastatic OSA.

View Figures

View References

1	Fromigue O, Hamidouche Z, Vaudin P, Lecanda F, Patino A, Barbry P, Mari B and Marie PJ: CYR61 downregulation reduces osteosarcoma cell invasion, migration, and metastasis. J Bone Miner Res. 26:1533–1542. 2011. View Article : Google Scholar : PubMed/NCBI
2	Zhang Y, Zhang L, Zhang G, Li S, Duan J, Cheng J, Ding G, Zhou C, Zhang J, Luo P, et al: Osteosarcoma metastasis: Prospective role of ezrin. Tumour Biol. 35:5055–5059. 2014. View Article : Google Scholar : PubMed/NCBI
3	Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS and Carbone M: Oncogene alterations in primary, recurrent and metastatic human bone tumors. J Cell Biochem. 63:37–50. 1996. View Article : Google Scholar : PubMed/NCBI
4	Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG and Healey JH: MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53:16–18. 1993.PubMed/NCBI
5	Wang ZQ, Liang J, Schellander K, Wagner EF and Grigoriadis AE: c-fos-induced osteosarcoma formation in transgenic mice: Cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 55:6244–6251. 1995.PubMed/NCBI
6	Cao Y, Jia SF, Chakravarty G, de Crombrugghe B and Kleinerman ES: The osterix transcription factor down-regulates interleukin-1 alpha expression in mouse osteosarcoma cells. Mol Cancer Res. 6:119–126. 2008. View Article : Google Scholar : PubMed/NCBI
7	Cao Y, Zhou Z, de Crombrugghe B, Nakashima K, Guan H, Duan X, Jia SF and Kleinerman ES: Osterix, a transcription factor for osteoblast differentiation, mediates antitumor activity in murine osteosarcoma. Cancer Res. 65:1124–1128. 2005. View Article : Google Scholar : PubMed/NCBI
8	Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP, Waring P, McArthur GA, Walkley CR, Holloway AJ, et al: Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol. 167:925–934. 2004. View Article : Google Scholar : PubMed/NCBI
9	Entz-Werlé N, Stoetzel C, Berard-Marec P, Kalifa C, Brugiere L, Pacquement H, Schmitt C, Tabone MD, Gentet JC, Quillet R, et al: Frequent genomic abnormalities at TWIST in human pediatric osteosarcomas. Int J Cancer. 117:349–355. 2005. View Article : Google Scholar : PubMed/NCBI
10	O'Farrill JS and Gordon N: Autophagy in osteosarcoma. Adv Exp Med Biol. 804:147–160. 2014. View Article : Google Scholar : PubMed/NCBI
11	Zhang P, Yang Y, Zweidler-McKay PA and Hughes DP: Critical role of notch signaling in osteosarcoma invasion and metastasis. Clin Cancer Res. 14:2962–2969. 2008. View Article : Google Scholar : PubMed/NCBI
12	Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 10:182–186. 2004. View Article : Google Scholar : PubMed/NCBI
13	Fromigué O, Hamidouche Z and Marie PJ: Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs. J Pharmacol Exp Ther. 325:595–600. 2008. View Article : Google Scholar : PubMed/NCBI
14	Fromigué O, Hamidouche Z and Marie PJ: Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. J Biol Chem. 283:30549–30556. 2008. View Article : Google Scholar : PubMed/NCBI
15	Fromigué O, Haÿ E, Modrowski D, Bouvet S, Jacquel A, Auberger P and Marie PJ: RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 13:1845–1856. 2006. View Article : Google Scholar : PubMed/NCBI
16	Yang GP and Lau LF: Cyr61, product of a growth factor-inducible immediate early gene, is associated with the extracellular matrix and the cell surface. Cell Growth Differ. 2:351–357. 1991.PubMed/NCBI
17	Fromigue O, Lagneaux L and Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 15:2211–2221. 2000. View Article : Google Scholar : PubMed/NCBI
18	Casey PJ and Seabra MC: Protein prenyltransferases. J Biol Chem. 271:5289–5292. 1996. View Article : Google Scholar : PubMed/NCBI
19	McTaggart SJ: Isoprenylated proteins. Cell Mol Life Sci. 63:255–267. 2006. View Article : Google Scholar
20	Hiraga T, Williams PJ, Mundy GR and Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 61:4418–4424. 2001.PubMed/NCBI
21	Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61:2602–2608. 2001.PubMed/NCBI
22	Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D and Redini F: Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 104:2522–2529. 2005. View Article : Google Scholar : PubMed/NCBI
23	Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W and van Valen F: The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs. 12:459–465. 2001. View Article : Google Scholar : PubMed/NCBI
24	Delarue FL, Adnane J, Joshi B, Blaskovich MA, Wang DA, Hawker J, Bizouarn F, Ohkanda J, Zhu K, Hamilton AD, et al: Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Oncogene. 26:633–640. 2007. View Article : Google Scholar
25	Sebti SM and Hamilton AD: Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: Lessons from mechanism and bench-to-bedside translational studies. Oncogene. 19:6584–6593. 2000. View Article : Google Scholar
26	Istvan E: Statin inhibition of HMG-CoA reductase: A 3-dimensional view. Atheroscler Suppl. 4:3–8. 2003. View Article : Google Scholar : PubMed/NCBI
27	Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD and Gaziano JM: The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst. 100:134–139. 2008. View Article : Google Scholar : PubMed/NCBI
28	Beri A, Sural N and Mahajan SB: Non-atheroprotective effects of statins: A systematic review. Am J Cardiovasc Drugs. 9:361–370. 2009. View Article : Google Scholar : PubMed/NCBI
29	Gonyeau MJ and Yuen DW: A clinical review of statins and cancer: Helpful or harmful? Pharmacotherapy. 30:177–194. 2010. View Article : Google Scholar : PubMed/NCBI
30	Babic AM, Kireeva ML, Kolesnikova TV and Lau LF: CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA. 95:6355–6360. 1998. View Article : Google Scholar : PubMed/NCBI
31	Bleau AM, Planque N and Perbal B: CCN proteins and cancer: two to tango. Front Biosci. 10:998–1009. 2005. View Article : Google Scholar : PubMed/NCBI
32	Menéndez JA, Mehmi I, Griggs DW and Lupu R: The angiogenic factor CYR61 in breast cancer: Molecular pathology and therapeutic perspectives. Endocr Relat Cancer. 10:141–152. 2003. View Article : Google Scholar : PubMed/NCBI
33	Jun JI and Lau LF: Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov. 10:945–963. 2011. View Article : Google Scholar : PubMed/NCBI
34	Hall-Glenn F and Lyons KM: Roles for CCN2 in normal physiological processes. Cell Mol Life Sci. 68:3209–3217. 2011. View Article : Google Scholar : PubMed/NCBI
35	Chen CC and Lau LF: Functions and mechanisms of action of CCN matricellular proteins. Int J Biochem Cell Biol. 41:771–783. 2009. View Article : Google Scholar :
36	Holbourn KP, Acharya KR and Perbal B: The CCN family of proteins: Structure-function relationships. Trends Biochem Sci. 33:461–473. 2008. View Article : Google Scholar : PubMed/NCBI
37	Leask A and Abraham DJ: All in the CCN family: Essential matricellular signaling modulators emerge from the bunker. J Cell Sci. 119:4803–4810. 2006. View Article : Google Scholar : PubMed/NCBI
38	Kubota S and Takigawa M: The role of CCN2 in cartilage and bone development. J Cell Commun Signal. 5:209–217. 2011. View Article : Google Scholar : PubMed/NCBI
39	Martirosyan A, Clendening JW, Goard CA and Penn LZ: Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: Potential therapeutic relevance. BMC Cancer. 10:1032010. View Article : Google Scholar : PubMed/NCBI
40	Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C and Emmerich B: First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol. 79:240–243. 2007. View Article : Google Scholar : PubMed/NCBI
41	van der Spek E, Bloem AC, Sinnige HA and Lokhorst HM: High dose simvastatin does not reverse resistance to vincristine, adriamycin and dexamethasone (VAD) in myeloma. Haematologica. 92:e130–e131. 2007. View Article : Google Scholar : PubMed/NCBI
42	van der Spek E, Bloem AC, van de Donk NW, Bogers LH, van der Griend R, Kramer MH, de Weerdt O, Wittebol S and Lokhorst HM: Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma. Haematologica. 91:542–545. 2006.PubMed/NCBI
43	Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, et al: Cyr61 down-modulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer. 125:2004–2013. 2009. View Article : Google Scholar : PubMed/NCBI
44	Nguyen N, Kuliopulos A, Graham RA and Covic L: Tumor-derived Cyr61(CCN1) promotes stromal matrix metalloproteinase-1 production and protease-activated receptor 1-dependent migration of breast cancer cells. Cancer Res. 66:2658–2665. 2006. View Article : Google Scholar : PubMed/NCBI
45	Manara MC, Perbal B, Benini S, Strammiello R, Cerisano V, Perdichizzi S, Serra M, Astolfi A, Bertoni F, Alami J, et al: The expression of ccn3 (nov) gene in musculoskeletal tumors. Am J Pathol. 160:849–859. 2002. View Article : Google Scholar : PubMed/NCBI
46	Perbal B, Zuntini M, Zambelli D, Serra M, Sciandra M, Cantiani L, Lucarelli E, Picci P and Scotlandi K: Prognostic value of CCN3 in osteosarcoma. Clin Cancer Res. 14:701–709. 2008. View Article : Google Scholar : PubMed/NCBI